Lincomycins primarily target Gram-positive bacteria. Clindamycin, a lincomycin derivative, shows broader activity against certain Gram-negative anaerobes.
Gram-positive bacteria susceptible to lincomycins include Staphylococcus aureus (including methicillin-resistant strains, although resistance is increasing), Streptococcus pneumoniae, and various streptococcal species. However, resistance is a growing concern, and susceptibility testing is crucial before treatment.
Clostridium difficile, a Gram-positive anaerobic bacterium responsible for antibiotic-associated colitis, is also susceptible. Clindamycin’s use is, however, carefully considered because it can trigger C. difficile infection.
Gram-negative bacteria generally exhibit less susceptibility. Exceptions include some anaerobic species like Bacteroides fragilis and Fusobacterium spp., which are often targeted with clindamycin.
Mycoplasma pneumoniae and Chlamydia pneumoniae, atypical bacteria, demonstrate some susceptibility to lincomycins.
Remember: This information offers a general overview. Actual susceptibility varies among bacterial strains, geographical location, and other factors. Always consult current antibiotic susceptibility testing reports for optimal treatment strategies.
